Hui Miao
Director/Board Member chez Beijing Zhendong Langdi Pharmaceutical Co., Ltd.
Profil
Hui Miao is currently the Director at Beijing Zhendong Langdi Pharmaceutical Co., Ltd.
Prior to this, Mr. Miao served as the President, Chief Executive Officer & Director at GuangYuYuan Chinese Herbal Medicine Co., Ltd.
from 2022 to 2024.
Mr. Miao completed their undergraduate degree at Renmin University of China.
Postes actifs de Hui Miao
| Sociétés | Poste | Début |
|---|---|---|
Beijing Zhendong Langdi Pharmaceutical Co., Ltd.
 Beijing Zhendong Langdi Pharmaceutical Co., Ltd. Pharmaceuticals: OtherHealth Technology Part of Fountainvest Partners (Asia) Ltd., Beijing Zhendong Langdi Pharmaceutical Co., Ltd. manufactures medicinal chemicals and botanical products. The private company is based in Beijing, China. Beijing Zhendong Langdi Pharmaceutical Co. was acquired by Shanghai Fanglang Enterprise Management Co. Ltd. from Shanxi Zhendong Pharmaceutical Co., Ltd. on October 28, 2021 for $895.09 million. The Chinese company was founded in 2003. | Director/Board Member | - |
Anciens postes connus de Hui Miao
| Sociétés | Poste | Fin |
|---|---|---|
| GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. | Chief Executive Officer | 09/04/2024 |
Formation de Hui Miao
| Renmin University of China | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Beijing Zhendong Langdi Pharmaceutical Co., Ltd.
Beijing Zhendong Langdi Pharmaceutical Co., Ltd. Pharmaceuticals: OtherHealth Technology Part of Fountainvest Partners (Asia) Ltd., Beijing Zhendong Langdi Pharmaceutical Co., Ltd. manufactures medicinal chemicals and botanical products. The private company is based in Beijing, China. Beijing Zhendong Langdi Pharmaceutical Co. was acquired by Shanghai Fanglang Enterprise Management Co. Ltd. from Shanxi Zhendong Pharmaceutical Co., Ltd. on October 28, 2021 for $895.09 million. The Chinese company was founded in 2003. | Health Technology |
